Jagpod CV 200mg/125mg Tablet is a combination antibiotic formulation containing Cefpodoxime Proxetil 200mg and Clavulanic Acid 125mg. Cefpodoxime Proxetil, a third-generation cephalosporin antibiotic, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, thereby effectively treating a variety of bacterial infections. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of cefpodoxime by preventing enzymatic degradation of the antibiotic by beta-lactamase-producing bacteria, thus extending its spectrum of activity against resistant strains. This combination is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, and other susceptible bacterial infections. Jagpod CV is effective against both gram-positive and gram-negative pathogens, including beta-lactamase-producing strains. The medication should be used according to susceptibility patterns and clinical judgment, with dosage adjustments as necessary based on renal function and severity of infection. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and rare occurrences of hepatic dysfunction. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Proper adherence to prescribed dosage and duration is critical to prevent resistance development and ensure therapeutic success.